• Molecular NameTolazamide
  • SynonymNA
  • Weight311.406
  • Drugbank_IDDB00839
  • ACS_NO1156-19-0
  • Show 3D model
  • LogP (experiment)1.45
  • LogP (predicted, AB/LogP v2.0)1.41
  • pka3.5 (25°), 5.7 (37.5°)
  • LogD (pH=7, predicted)0.27
  • Solubility (experiment)Insoluble
  • LogS (predicted, ACD/Labs)(ph=7)-1.71
  • LogSw (predicted, AB/LogsW2.0)0.15
  • Sw (mg/ml) (predicted, ACD/Labs)0.18
  • No.of HBond Donors2
  • No.of HBond Acceptors6
  • No.of Rotatable Bonds3
  • TPSA86.89
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyAn oral blood glucose lowering drug used for people with Type 2 diabetes.
  • Absorption_valueN/A
  • Absorption (description)Rapidly and well absorbed from the gastrointestinal tract.
  • Caco_2N/A
  • BioavailabilityN/A
  • Protein binding94.0
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmTolazamide is metabolized to five major metabolites ranging in hypoglycemic activity from 0 to 70%.
  • Half life5 h
  • ExcretionRenal (85%) and fecal (7%)
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityOverdosage of sulfonylureas can produce hypoglycemia. Severe hypoglycemic reactions with coma, seizure, or other neurological impairment occur infrequently, but constitute medical emergencies requiring immediate hospitalization.
  • LD50 (rat)N/A
  • LD50 (mouse)LD50=1000